This review focuses on the role of Aβ in AD pathogenesis in Down syndrome and current approaches for imaging Aβ in vivo. We will describe how Aβ deposits with age, the posttranslational modifications that can occur, and detection in biofluids. Three unique case studies describing partial trisomy 21 cases without APP triplication, and the occurrences of low level mosaic trisomy 21 in an early onset AD patient are presented. Brain imaging for Aβ includes those by positron emission tomography and ligands (Pittsburgh Compound B, Florbetapir, and FDDNP) that bind Aβ have been published and are summarized here. In combination, we have learned a great deal about Aβ in DS in terms of characterizing age of onset of this pathology and it is exciting to note that there is a clinical trial in DS targeting Aβ that may lead to clinical benefits.

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalFree Radical Biology and Medicine
StatePublished - Jan 2018

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.


  • Cerebrovascular pathology
  • Neuroimaging
  • Partial trisomy 21
  • Pittsburgh Compound B
  • Trisomy 21

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)


Dive into the research topics of 'Down syndrome, beta-amyloid and neuroimaging'. Together they form a unique fingerprint.

Cite this